Cell Therapy
At Bristol Myers Squibb, we are committed to transforming patients' lives with blood cancers by utilising CAR-T cell therapy.
CAR-T cell therapy represents the next step in cancer treatment, giving patients and their families new hope and real options. It is an advanced, personalised approach to treating blood cancers such as lymphoma and multiple myeloma. We believe in the power of collaboration, innovation and patient-centred care to develop life-changing therapies.
For over fifty years, Bristol Myers Squibb has been a leader in discovering, developing and delivering innovative medicines for severe hematological diseases. Today, with advances like CAR-T cell therapy, we are redefining what is possible for patients with hematological cancers.
- Research and development: We continuously invest in research to further improve CAR-T therapies, increase their efficacy and put more patients on the path to remission.
- Optimising accessibility and quality of healthcare: We are committed to ensuring that patients have access to the latest innovations in hematology treatment, including personalised CAR-T therapies that can make a difference.
- Working together to improve quality of life: We collaborate with healthcare professionals, patient organisations, and carers to ensure every patient receives the best possible care and support during their treatment.
CAR-T cell therapy is a highly personalised treatment in which the patient’s T-cells are modified to fight cancer cells more effectively. For patients with difficult-to-treat haematological cancers such as lymphoma or multiple myeloma, CAR-T therapy offers a new way forward.
The treatment process begins with the removal of T-cells from the patient. These cells are then genetically modified to express chimeric antigen receptors (CARs), enabling T-cells to recognise and destroy cancer cells. Once the CAR-T cells are modified, they are infused into the patient, where they can detect and attack the cancer.
Bristol Myers Squibb is proud to operate a state-of-the-art CAR-T manufacturing facility in Leiden, the Netherlands, where we produce these advanced therapies to support our CAR-T initiatives. This facility will allow us to bring personalised cell therapies closer to European patients, ensuring faster access and greater availability of these transformative treatments.
Our commitment to investing in local infrastructure supports patients across Europe and provides the resources needed for cutting-edge medical innovation.